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Abstract
Objective: Osteoarthritis (OA) is the most common form of arthritis worldwide. Pain and reduced function are the main
symptoms in this prevalent disease. There are currently no treatments for OA that modify disease progression; therefore
analgesic drugs and joint replacement for larger joints are the standard of care. In light of several recent studies reporting
the use of bisphosphonates for OA treatment, our work aimed to evaluate published literature to assess the effectiveness of
bisphosphonates in OA treatment.
Methods: Literature databases were searched from inception to the 30th June 2012 for clinical trials of bisphosphonates to
treat OA pain. Data was appraised and levels of evidence determined qualitatively using best evidence synthesis from the
Cochrane Collaboration. The two largest studies were conducted with risedronate in the treatment of knee OA, for which
meta-analyses were performed for pain and functional outcomes.
Results: Our searches found 13/297 eligible studies, which included a total of 3832 participants. The trials recruited
participants with OA of the hand (n = 1), knee (n = 8), knee and spine (n = 3), or hip (n = 1). Our meta-analysis of the two
largest knee studies using risedronate 15 mg showed odds ratios favouring placebo interventions for the Western Ontario
and McMaster Universities Arthritis Index (WOMAC) pain (1.73), WOMAC function (2.03), and WOMAC stiffness (1.82).
However, 8 trials (61.5%) reported that bisphosphonates improve pain assessed by VAS scores and 2 (38.5%) reported
significant improvement in WOMAC pain scores compared to control groups.
Conclusions: There is limited evidence that bisphosphonates are effective in the treatment of OA pain. Limitations of the
studies we analysed included the differences in duration of bisphosphonate use, the dose and route of administration and
the lack of long-term data on OA joint structure modification post-bisphosphonate therapy. Future more targeted studies
are required to appreciate the value of bisphosphonates in treating osteoarthritis pain.
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Introduction
Osteoarthritis (OA) is the commonest form of arthritis
worldwide and is a major cause of disability and pain. In 1999/
2000, OA cost the UK economy nearly £3.2 billion in reduced
production [1]. In an ageing population, the prevalence of OA is
expected to increase, particularly as there are currently no
treatments that delay or halt the progression of disease. The
mainstay of treatments currently approved by the UK National
Institute for Health and Clinical Excellence (NICE) include pain
control with oral or topical analgesic drugs e.g. NSAIDs, opioids,
capsaicin, accompanied by physical therapies to maintain function
[2]. In people where optimal medical management is insufficient
to control symptoms, joint replacement surgery is considered in
large weight bearing joints such as the hip and knee. However,
pain in people with OA is increasingly documented even after joint
replacement surgery. In a systematic review of outcomes, the
proportion of people with unfavourable long-term pain following
total hip replacement (THR) ranged from 7% to 23%, and 10% to
34% following total knee replacement (TKR) [3]. There is
therefore an urgent need to address pain management in people
with OA.
In recent years, several studies have investigated the merits of
bisphosphonates in the treatment of OA. Traditionally used for
the treatment of osteoporosis, bisphosphonates target osteoclast
resorption and have been proven to be effective in reducing
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fracture rates in people with established osteoporosis [4].
Bisphosphonates can attach to hydroxyapatite binding sites on
bony surfaces, particularly those which are undergoing active bone
resorption [5]. When osteoclasts begin to resorb bone impregnated
with bisphosphonate, the bisphosphonate released during resorp-
tion impairs the ability of osteoclasts to form the ruffled border, to
adhere to the bony surface and to produce the protons required for
continued bone resorption [6]. Bisphosphonates also reduce
osteoclast activity by reducing osteoclast progenitor development
[7]. There is much less information available on how bisphospho-
nates could be effective in the treatment of OA, although they
could act through several mechanisms. Osteoarthritis is known to
be associated with altered bone turnover, particularly beneath the
thickened subchondral plate, with altered flexibility and increased
ability to microfracture [8]. It is therefore possible that bisphos-
phonates could be used to target the osteoclast-mediated extension
of channels from marrow spaces into the non-calcified articular
cartilage. It has previously been suggested that the loss of
osteochondral integrity in OA lesions can expose the subchondral
nerves to pro-inflammatory and pain mediating molecules from
the synovial fluid, which could permit growth of sensory nerves
into non-calcified articular cartilage [9]. It has also been suggested
that osteoclasts may reduce pH at the osteochondral junction,
which could lead to sensitization and activation of sensory nerves
through ion channels on their peripheral terminals [10]. Recent
studies from an animal model of OA also suggested that
bisphosphonates could target subchondral bone turnover and
synovitis in OA [11].
The most common outcome measures used for pain assessment
in musculoskeletal pain studies include the Western Ontario and
McMaster Universities Arthritis Index (WOMAC) and visual
analogue score (VAS). The scoring systems described have been
validated in many studies internationally and now form the core
dataset for many studies upon which national bodies base
recommendations for care [2]. The WOMAC scale has a widely
used standardised questionnaire used by health professionals to
evaluate the condition of patients with OA of the knee and hip,
including pain, stiffness and physical functioning of the joints [12].
The WOMAC measures five items for pain (score range 0–20),
two for stiffness (score range 0–8) and 17 for functional limitation
(score range 0–68). Physical functioning questions cover everyday
activities such as stair use, standing, bending, walking, sitting and
household duties. In contrast, the visual analogue score for pain
comprises of a 0–10 rating scale for pain and is well validated
internationally in many pain studies [13]. Other studies in our
analysis utilised variations of the VAS, also known as the visual
rating scale (VRS). Our study has therefore focused primarily on
the WOMAC and VAS pain and function outcome measures for
meta-analyses and synthesis of studies retrieved since they are the
most widely used pain outcome measures in the studies evaluated.
Several international studies have been conducted in recent
years to assess whether bisphosphonates can target OA pain.
However, to our knowledge, no previous systematic reviews exist
on the use of bisphosphonates in OA. We have therefore
systematically reviewed the current available literature and discuss
our evaluation through a meta-analysis and ‘levels of evidence’
approach where appropriate.
Materials and Methods
The systematic review methods were conducted in accordance
with PRISMA guidelines [14]. The study protocol was published
on the PROSPERO registry (Registration Number:
CRD42012002541).
Data Sources, Searches and Extraction
All searches were conducted from database inception to the 30th
June 2012 by one reviewer (AD). The primary search was
conducted using the electronic databases AMED, CINAHL,
EMBASE, MEDLINE, PUBMED, Web of Knowledge, the
Cochrane Library and Biomed Central. Secondary searches were
conducted by evaluating the unpublished and grey evidence
including: the WHO International Clinical Trials Registry
Platform, Current Controlled Trials, DART Europe, rian.ie,
British Library Archive & Manuscripts, British Library Theses,
OT Seeker, Centre for Reviews and Dissemination, Campbell
Library of Systematic Reviews, HMIC, Prospero, ERIC, MIT
Theses, WHO Library & Information Networks for Knowledge
Database, the United States National Institute of Health Trials
Registry, OpenGrey (System for Information on Grey Literature
in Europe). The MeSH terms and Boolean operators used are
shown in Figure 1.
Study Eligibility
Two authors (AD/NS) screened the title and abstract of the
studies identified from the database searches using the following
criteria: randomised controlled trials (RCT) comparing the use of
a bisphosphonate therapy to: a non-treatment control, a placebo,
another bisphosphonate therapy or to an alternative pharmaco-
logical intervention. Trials where participants presented with
symptomatic OA of any anatomical region, such as knee, hips,
spine and hand were included. Studies where participants had
primarily back pain and/or spinal OA were not included. This is
justified since the relationship between radiographic OA and back
pain is unclear [15]. Any dosage or delivery method and follow-up
periods were considered in the study. There were no limits on
severity or duration of OA, nor language of study. Exclusion
criteria included in vitro, animal studies and populations where the
predominant pathology was not OA.
Data Extraction
Data from all eligible papers was extracted by one author (AD)
and independently verified by two reviewers (NS, TS). Data
extracted included: therapy, diagnosis (including diagnostic criteria
for OA), inclusion/exclusion criteria, sample size, cohort age,
gender, duration of intervention, primary and secondary outcome
Figure 1. The MeSH terms and Boolean operators used for
evaluation.
doi:10.1371/journal.pone.0072714.g001
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measurements, follow-up period, and outcomes recorded at each
follow-up period.
Outcome Measurements
The primary outcome of this evaluation was perceived pain,
measured using validated pain assessment scoring systems
including visual analogue scale (VAS), a visual rating scale
(VRS) or evaluation with the Western Ontario and McMaster
Universities Arthritis (WOMAC) index. Secondary outcomes
included the assessment of joint structural changes, indirect pain
(such as assessment via skin impedance studies), blood and urine
analyses of cartilage and bone turnover biomarkers e.g. collagen
type 1 cross-linked C-telopeptide (CTX-II) and collagen type 1
cross-linked N-telopeptide (NTX-I) and use of analgesics post-
therapy.
Assessment of Study Quality
Each of the included studies were assessed for methodological
quality using the Critical Appraisal Skills Programme (CASP)
guidelines [16]. This tool has been adopted widely in previous
reviews of musculoskeletal clinical studies [17,18]. Each included
paper was scored by one reviewer (AD) and independently verified
by a second (TS). Any disagreements in appraisal score were
discussed and resolved by a third reviewer (CH).
Data Analysis
Study homogeneity was assessed visually by examining the data
extraction tables. This identified considerable heterogeneity in
relation to the anatomical regions assessed, the type of bisphos-
phonate and dosage administered, and the comparative interven-
tion used. There was also considerable variability with respect to
the follow-up periods assessed. However, for the two studies of
bisphosphonates in knee OA, a meta-analysis was appropriate and
performed since the numbers were large enough for comparison
with between-study homogeneity as previously described [19].
Briefly, statistical heterogeneity was evaluated with Chi2 and I2
statistical tests. When Chi2 equated to p#0.10 and I2$20%, a
random-effects statistical model was undertaken. When Chi2
equated with p.0.10 and I2 was ,20% a fixed–effects model was
used. For continuous outcomes, mean difference (MD) or
standardised mean difference (SMD) was calculated, with corre-
sponding 95% confidence interval (CI). For each analysis, this was
also analysed through a corresponding forest-plot. All statistical
analyses were conducted on RevMan version 5.1 (Review
Manager (RevMan) [Computer program] Copenhagen: The
Nordic Cochrane Centre, Cochrane Collaboration, 2011).
For the remaining studies, a qualitative approach to data
synthesis was performed to assess the level of evidence of each
included study [19]. The approach described is an alternative to
pooling of association sizes when the included studies are
heterogeneous and has also been utilised in other systematic
reviews in OA [20,21]. The synthesis was conducted and rated as
suggested by the Cochrane Collaboration at five levels: strong;
moderate; limited; conflicting; and no evidence. The primary
outcome assessed was change in pain measures.
Sensitivity analyses by defining other cut-offs (median score of
all studies instead of mean) of high quality studies were performed.
A single trial that investigated multiple features (pain and
structural change in OA) which were reported in multiple papers,
was counted as a single study.
Results
Search Strategy
The results of the literature search strategy identified a total of
322 studies (Figure 2). A total of 13 studies were deemed eligible
and included in this systematic review. This included the removal
of duplicates (25 studies), the removal of studies deemed non-
eligible based on title and abstract screening (265 studies) and a
final 19 studies considered ineligible due to: not being a RCT
study (n= 4); studying a non-OA population (n= 5); not being an
original publication (n = 7); presenting no pain outcome (n= 1);
being a conference abstract that has since been superseded by a
full publication (n = 1); or having no comparison group (n= 1).
Characteristics of Included Studies
Of the 13 eligible studies, one study investigated bisphospho-
nates in the treatment of hand OA [22], eight studies focused on
knee OA and bisphosphonates [23–30] whilst three studies
recruited people with knee and back/spinal OA [31–33]. One
study investigated hip OA and bisphosphonates [34].
Study Quality Assessment
The results of the CASP appraisal illustrate that the current
evidence-base presented with a number of significant methodo-
logical limitations (Table 1). Strengths of the current evidence-base
include a clear definition of the study populations (100%),
construction of clear research questions (92%), definition of OA
and its diagnosis (77%) and random allocation of participants to
intervention received (92%). However, a number of methodolog-
ical weaknesses limited the quality of the evidence-base. Only five
studies (38%) blinded the assessor to group allocation. A total of
four studies (31%) did not account for all participants at the end of
the study, with only nine studies (69%) assessing for potential
baseline imbalance prior to commencing study interventions. A
total of 10 studies (77%) appropriately analysed their data and 11
studies (85%) appropriately interpreted their data following
analysis.
Study Demographics
The study demographics, clinical study drug use and outcomes
are presented in Table 2. In total 3832 participants were reviewed,
with a mean age range from 47 to 75 years. In the studies that
documented gender, the cohort consisted of 80% women,
identified in nine studies. A variety of bisphosphonates were
assessed: clodronate in two studies [22,26] alendronate in four
studies [25,29,32,34] risedronate in five studies [23,24,27,30,32]
etidronate in two studies [30,32] and one study assessed zoledronic
acid [28]. Follow-up periods ranged from five weeks to 24 months.
Risedronate and Knee OA: Meta-analysis
Two large randomised controlled studies have been conducted
of risedronate use in knee OA [23,24]. The studies reported by
Bingham et al. [23] and Spector et al. [24] formed the basis of a
meta-analysis. The results of the meta-analyses are presented in
Figure 3 & 4. This identified that for WOMAC pain, there was no
statistically significant difference between risedronate and placebo
for 5 mg daily (OR: 0.09; 95% CI: 21.24, 1.43; Figure 3A); and
15 mg weekly (OR: 1.73; 95% CI: 2.56, 4.02; Figure 3A). No
significant effects were observed for higher doses of risedronate
35 mg and 50 mg weekly respectively on single-item analyses.
Further secondary analyses were conducted using the total
WOMAC score. This reported no statistically significant differ-
ence between risedronate and placebo interventions at 5 mg daily
(Odd Ratio (OR): 20.33; 95% Confidence Intervals (CI): 22.41,
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1.75; Figure 3B), or 15 mg weekly (OR: 2.06; 95% CI: 20.73,
4.84; Figure 3B). At higher risedronate doses of 35 mg and 50 mg
weekly where only a single-item analysis could be performed, no
significant improvement in WOMAC outcome was observed.
Similarly, there was no statistically significant difference for
risedronate on WOMAC function at a 5 mg daily dose (OR:
20.18; 95% CI: 22.42, 2.06; Figure 4A) or 15 mg weekly dose
(OR: 2.03; 95% CI: 20.66, 4.72; Figure 4A). At higher doses of
35 mg and 50 mg weekly risedronate, no significant effects were
observed versus placebo. WOMAC stiffness subscale also demon-
strated no statistically significant differences between the groups at
5 mg daily dose (OR: 20.45; 95% CI: 24.82, 3.92; Figure 4B),
and 15 mg weekly dose (OR: 1.82; 95% CI: 20.09, 3.74;
Figure 4B). Our meta-analysis results show that for standardised
WOMAC outcomes, no significant effects were observed at any
dose of risedronate compared with placebo.
In addition, there were no statistically significant differences or
trends were noted for any dose of risedronate. Similarly there was
no difference between the five groups with respect to radiographic
joint space narrowing, joint space width, or osteophyte formation
during the 24 month follow-up (p.0.05). There was a significant
decrease in collagen type 1 cross-linked N-telopeptide levels, or
NTX-1, which was dose-dependent in the risedronate group
during follow-up (p,0.05).
Spector et al. [24] reported no statistically significant difference
in loss of joint space width (p = 0.28) between the different
intervention groups and placebo during a 12 month follow-up
period. There was a statistically greater improvement in patient
global assessment (p,0.001) and reduced use of walking aids
(p = 0.009) between the 15 mg weekly risedronate group com-
pared to the placebo group at 12 months. This was not evident in
the 5 mg/day cohort. In additional biomarker analysis, there was
a statistically significant decrease in mean urinary c-terminal
crosslinking telopeptide of type II collagen (CTX-II; marker of
cartilage turnover) and N-terminal crosslinking telopeptide of type
I collagen (NTX-I; marker of bone absorption) values in the 15 mg
risedronate weekly group compared to the placebo group
(p,0.05).
Bisphosphonates and Knee OA: Narrative Research
Synthesis
Estrogen vs. Raloxifene vs. Alendronate vs. No
treatment. Carbone et al. [25] compared the use of alendronate
to oestrogen and raloxifene in a study of 818 women. The authors
found no significant association between overall use of anti-
resorptive drugs and the presence of knee pain and radiographic
changes of OA of the knee (p.0.05). Use of alendronate, but not
oestrogen, was associated with less severity of knee pain as assessed
Figure 2. PRISMA flow diagram utilised for systematic review.
doi:10.1371/journal.pone.0072714.g002
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Figure 3. Meta-analysis of knee OA studies for WOMAC pain and total WOMAC outcomes.
doi:10.1371/journal.pone.0072714.g003
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by WOMAC scores. Whilst there was no statistically significant
difference between the intervention groups in WOMAC score
(p.0.05), there were statistically improved scores in the alen-
dronate group compared to the no-treatment group (p,0.05).
There was no statistically significant difference between the three
groups receiving alendronate, oestrogen or raloxifene in response
to the presence or absence of knee symptoms or radiological OA in
the tibiofemoral (p$0.90), patellofemoral (p$0.12) compartments
or the whole knee (p$0.43). There was no statistically significant
difference between the three intervention groups in bone attrition,
osteophytes, BML or cartilage lesions (p.0.05).
Clodronate (0.5 mg I.A./week; 1.0 mg I.A./week; 2.0 mg
I.A./week; 2 I.A injections, 1.0 mg/week) vs. Hyaluronic
acid (20 mg/week). Rossini et al. [26] compared the prescrip-
Figure 4. Meta-analysis of knee OA studies for WOMAC function and stiffness scales.
doi:10.1371/journal.pone.0072714.g004
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tion of different dosages of clodronate to hyaluronic acid with
people with knee OA. They reported no statistically significant
difference between the groups with respect to VAS pain (p.0.05)
or mobility scores (p$0.06) during the initial five weeks. However
after adjusting for multiple comparisons and paracetamol use, the
authors reported that there was significantly less pain in those
allocated to the intra-articular injections 1 mg compared to the
hyaluronic acid group (p,0.01). There was no statistically
significant difference between the groups with respect to side
effects (p.0.05).
Risedronate (2.5 mg/day) and Exercise vs. Glucosamine
and Exercise vs. Exercise alone. Kawasaki et al. [27] reported
no statistically significant difference in additive events between
their three intervention arms, although an improvement in
individual pain scores was seen after 18 months. There was no
statistically significant difference between the groups in functional
outcomes at 18 months as assessed with the Japan Orthopaedic
Association score (p.0.05), VAS pain (p.0.05), WOMAC score
(p =.0.05), joint space width (p.0.05) or use of NSAIDS
(p.0.05).
Zoledronic Acid (5 mg/100 ml) vs. Placebo. Laslett et al.
[28] compared clinical outcomes between a single in-fusion of
zoledronic acid (5 mg/100 ml) to a placebo control group. This
trial showed significant improvements in pain using the VAS at six
months, which was the primary endpoint of this study. There was
a 214.5 mm reduction in VAS at six months. Of note, there was
no significant improvement in VAS at three or 12 months. Change
in the Knee Injury and Osteoarthritis Outcome Score (KOOS)
was not significant at any time point in this study. The authors also
reported a reduction in total BML area of greater magnitude in
the zoledronate group compared with placebo after six months
(2175.7 mm2; 95% CI: 2327.2 to 224.3) with a non-statistically
significant trend after 12 months (2146.5 mm2; 95% CI: 2307.5
to 14.5). With respect to adverse outcomes, the prevalence of
adverse events in the zoledronate group was 90%. Of these
adverse events, the most common was cold or flu symptoms, which
was 78% of the 90% total.
Alendronate (oral: 70 mg/week) vs.
Placebo. Alendronate (oral: 70 mg/week) was compared to a
placebo control in a trial by Jokar et al. [29]. The authors reported
no statistically significant difference between the two groups at six
month follow-up for WOMAC functional score (p.0.05), use of
NSAIDs (p=.0.05) frequency of adverse events and side effects
(p =.0.05). The most common side-effects were dyspepsia
(alendronate = 15%; placebo= 10%) and heart burn (alendro-
nate = 10%; placebo= 10%).
Bisphosphonates in Hand OA
Clodronate (300 mg i.v.) vs. hydroxychloroquine (i.m.
100 mg) at 3 months. One study compared the use of a
bisphosphonate with hydroxychloroquine [22]. A statistically
significant decrease in pain during the 24 month follow-up in
the clodronate group (p= 0.02) was reported, and greater
physician and patient global assessment scores in the clodronate
group compared to the hydroxychloroquine group (p,0.001).
Bisphosphonates in Knee and Spine OA
Etidronate (66 mg/day; 133 mg/day; 200 mg/day) vs.
No-Treatment Control. Fujita et al. [30] reported statistically
significantly lower VRS subjective pain, and mean fall in skin
impedance in the three etidronate dosage groups, compared to the
no-treatment control (p,0.001) during the 12 months follow-up
period. The authors also reported a positive relationship between
the dose of etidronate to bone mineral density and pain, where an
increased effect of etidronate was associated with increased bone
mineral density and reduced pain (p,0.05).
Risedronate (2.5 mg/day) vs. Etidronate (200 mg/day)
vs. Alendronate (5 mg/day) vs. No-Treatment Control. A
comparison of risedronate, etidronate and alendronate was made
to a no-treatment control group in Fujita et al. [32] with
participants who presented with symptomatic knee and spinal
OA. There was a significant reduction in pain as assessed by a fall
in skin impedance and by subjective pain response with
bisphosphonates compared to the no-treatment control
(p,0.001). There was no statistically significant difference between
the three bisphosphonate groups (p.0.05). Previously, Fujita et al.
[31] compared risedronate versus calcitonin in OA in the knee and
spine and found similar analgesic outcome measures in both arms
of the study (p.0.05).
Bisphosphonates in Hip OA
Alendronate (35 mg/week) vs. Calcium Lactate (600 mg/
day). One study assessed the use of bisphosphonates with hip
OA [34]. The use of alendronate (35 mg/week) provided
statistically significant better pain reduction compared to those
randomised to receive calcium lactate (600 mg/day) at 24 months.
There was no statistically significant difference in radiological OA
progression (p.0.05).
Level of Evidence Assessment
Based on the studies evaluated above, we have synthesised levels
of evidence by assessing the quality of the studies. Our meta-
analysis of the two largest knee OA studies showed no statistically
significant difference in pain or functional outcomes assessed by
WOMAC with risedronate over placebo arms at doses of
risedronate at doses of 5 mg daily, or 15 mg, 35 mg and 50 mg
weekly. The remaining studies, which could not be evaluated by
meta-analysis, showed that bisphosphonates reduce pain greater
than placebo or non-treatment controls in OA in Asian, European
and North American populations when assessed by VAS and
WOMAC outcomes. There was heterogeneity across the studies
analysed, with variability in anatomical position of disease, gender
studied, doses, route and frequency of drug administration.
Discussion
The outcome of our analysis concludes that bisphosphonates
demonstrate limited evidence for pain modulation in OA. There is
little clinical information available from published studies of the
effects of bisphosphonates on the most significant correlates of pain
in OA, which include synovitis and bone marrow lesions [35]. The
studies assessed highlight that OA is a heterogeneous disease
varying with time and may explain why none of the studies
reported difference in both synovitis and BML at follow-up over
several years. Nonetheless specific studies such as Laslett et al. [28]
and Nishii et al. [34] attempted to examine modulation in BML by
bisphosphonates temporally over the course of their clinical
studies. Adequate targeting of OA participants to specific time-
points in their disease process when such changes may occur
would be a valuable addition to the evidence-base or correlation of
bisphosphonate use with not only clinical pain outcomes but also
progression of BML and/or synovitis. The correlation of pain
outcomes including VAS and WOMAC with radiographic
correlates of pain such as synovitis and BML are important issues
to be considered for future clinical trial designs of bisphosphonates.
However, the studies described may only explain a small
proportion of pain variance and other mediators, as yet
uncharacterised, may be more important mediators of OA pain.
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From a safety perspective, regarding the use of bisphosphonates
in OA populations, the most common adverse events to
bisphosphonate use were gastrointestinal, principally dyspepsia
complications. There was no statistically significant difference in
these events in those prescribed bisphosphonates compared to
non-treatment or placebo. Prescribed medications were otherwise
well tolerated with no major significant effect on blood counts,
renal and liver function.
Much is yet to be learned with respect to the progression of OA
and the relation between level of pain experienced by OA
populations in comparison to regions of structural change e.g. joint
space narrowing, bone marrow lesion size and synovitis. There is
therefore an urgent need for further studies of bisphosphonates in
OA in clearly defined subsets, coupled with robust radiographic
analysis by cartilage integrity, BML size/composition, synovitis,
joint space narrowing and evaluation of clinical biomarkers to
more fully evaluate agents that could halt the onset and/or
progression of OA.
Future studies targeted at assessing bisphosphonate use for the
management of OA would benefit by selecting specific phenotypes
of participants in order to assess which groups may benefit most
from intervention. Considerations would need to include staging
and severity of osteoarthritis, not only perhaps assessed by joint
space narrowing, but also to include site and size of bone marrow
lesions, degree of synovitis and joint space narrowing, which could
be assessed using standardized scoring systems such as the
Magnetic Resonance Imaging Knee Osteoarthritis Score
(MOAKS) [36]. Since the most widely accepted pain and
functional outcome data are recorded using WOMAC and
VAS, future trials would need to include such measures in order
to make valid comparisons with existing studies. The temporal
sequence of the effect of the bisphosphonate intervention also
needs to be considered carefully in future studies, with not only
pain and functional outcome measures, but also structural
modification effects including bone marrow lesion size, synovitis
and joint space narrowing measures. Since OA is a chronic long-
term disease in which any pharmacological intervention would
need to be efficacious and tolerated over a significant period of
time, long-term follow-up data beyond one year would also be
most helpful in determining long-term effects and tolerability of
bisphosphonates in OA.
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